Literature DB >> 2403773

Ibuprofen in acute-care therapy.

W B Rockwell1, H P Ehrlich.   

Abstract

Ibuprofen is a potent cyclooxygenase inhibitor known to reduce the production of arachidonic acid metabolites. Prostacyclin and thromboxane are well-studied metabolites that play a prominent role in inflammation. Many of the effects of ibuprofen can be linked to its anti-inflammatory properties. Beneficial results from ibuprofen therapy have been documented, and more widespread use of the drug seems indicated. Conditions ranging from immunologic response to trauma and sepsis to postburn lung dysfunction to wound edema are improved by the use of ibuprofen. The fact that ibuprofen is effective in the various conditions detailed above, while other steroidal and nonsteroidal drugs are effective only in selective instances, increases the value of ibuprofen. Other properties of the drug, aside from its anti-inflammatory effects, are not as well studied and not as well known. Their importance, however, should not be overlooked. Superoxide radical tissue injury may be very important in acute injury and this phenomenon needs further study. In several studies ibuprofen has been shown to antagonize this type of injury. Similarly fibrinolysis inhibition is known to occur in burn wounds, but its role in other injuries is unknown. The antagonism of this inhibitor by ibuprofen maintains vascular patency. The clinical use of ibuprofen will increase as research further elucidates the mechanisms of tissue injury in acute situations and the many and varied mechanisms of action of ibuprofen.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403773      PMCID: PMC1357898          DOI: 10.1097/00000658-199001000-00014

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  60 in total

1.  The release of prostaglandins from lung and other tissues.

Authors:  P Piper; J Vane
Journal:  Ann N Y Acad Sci       Date:  1971-04-30       Impact factor: 5.691

2.  Tolerance and pharmacology of ibuprofen.

Authors:  C D Brooks; C A Schlagel; N C Sekhar; J T Sobota
Journal:  Curr Ther Res Clin Exp       Date:  1973-04

3.  Anti-inflammatory drugs in the vascular response to burn injury.

Authors:  H P Ehrlich
Journal:  J Trauma       Date:  1984-04

4.  Evaluation of ibuprofen (Motrin). A new antirheumatic agent.

Authors:  J R Lewis
Journal:  JAMA       Date:  1975-07-28       Impact factor: 56.272

5.  Treatment of experimental canine endotoxin shock with ibuprofen, a cyclooxygenase inhibitor.

Authors:  P M Almqvist; M Kuenzig; S I Schwartz
Journal:  Circ Shock       Date:  1984

6.  Postburn immunosuppression in an animal model. II. Restoration of cell-mediated immunity by immunomodulating drugs.

Authors:  J Hansbrough; V Peterson; R Zapata-Sirvent; H N Claman
Journal:  Surgery       Date:  1984-03       Impact factor: 3.982

7.  Arachidonic acid metabolites mediate early burn edema.

Authors:  F Alexander; M Mathieson; K H Teoh; W V Huval; S Lelcuk; C R Valeri; D Shepro; H B Hechtman
Journal:  J Trauma       Date:  1984-08

8.  Ibuprofen and diphenhydramine reduce the lung lesion of endotoxemia in sheep.

Authors:  D L Traber; T Adams; N Henriksen; L D Traber
Journal:  J Trauma       Date:  1984-09

9.  Promotion of vascular patency in dermal burns with ibuprofen.

Authors:  H P Ehrlich
Journal:  Am J Med       Date:  1984-07-13       Impact factor: 4.965

10.  Increased survival of endotoxin-injected dogs treated with methylprednisolone, naloxone, and ibuprofen.

Authors:  P M Almqvist; B Ekström; M Kuenzig; U Haglund; S I Schwartz
Journal:  Circ Shock       Date:  1984
View more
  2 in total

1.  Effects of non-steroidal anti-inflammatory drugs on flexor tendon rehabilitation after repair.

Authors:  Alireza Rouhani; Ali Tabrizi; Ehsan Ghavidel
Journal:  Arch Bone Jt Surg       Date:  2013-09-15

2.  Effects of ibuprofen on the physiology and outcome of rabbit endotoxic shock.

Authors:  Ilhami Celik; Ayhan Akbulut; S Sirri Kilic; Ali Rahman; Pervin Vural; Mukaddes Canbaz; Suleyman Felek
Journal:  BMC Infect Dis       Date:  2002-10-31       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.